Peetz Christopher sold $2.4M of MIRM
Peetz Christopher (CHIEF EXECUTIVE OFFICER) sold 20,000 shares of Mirum Pharmaceuticals, Inc. (MIRM) at an average of $122.27 ($121.65–$124.79, $2.45M total) across 4 trades on 2026-07-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new fact is the disclosed sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan; it does not include any new guidance, trial results, or regulatory updates.
Market read
Traders may note the insider sale for sentiment, but it is unlikely to change the fundamental outlook absent other catalysts.
What to watch
The article does not state tax, diversification, or liquidity needs; without those details, interpreting directionally is unreliable.
Background
The article is an SEC Form 4 insider transaction disclosure for Mirum Pharmaceuticals, Inc.
Ticker impact
SEC Form 4 shows CEO Peetz Christopher sold 20,000 shares of Mirum Pharmaceuticals in open-market trades totaling about $2.45M.
Likely minimal immediate price impact; any effect would be sentiment-driven and short-lived.
The filing is a routine Form 4 disclosure, explicitly notes a pre-arranged 10b5-1 plan, and provides no new company-specific operational or financial information.
Market effects
No sector read-through; this is company-specific insider trading disclosure without new clinical, regulatory, or product data.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with perceived valuation risk, so traders may watch for follow-on insider activity.
Key entities
- issuerMirum Pharmaceuticals, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderPeetz Christopher
CEO and reporting person who sold shares.
